Nihon Schering, Daiichi Radioisotope Laboratories to Collaborate in Sales of Radioimmunotherapy Agent Zevalin.Tokyo, Japan, July 10, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Nihon Schering announced on June 4 that it signed a joint business contract with Daiichi Radioisotope radioisotope: see radioactive isotope. Radioisotope (biology) A radioactive isotope used in studying living systems, such as in the investigation of metabolic processes. Laboratories (DRL DRL Bureau of Democracy, Human Rights and Labor (US State Department) DRL Daytime Running Lights DRL Department of Regulation and Licensing (real estate) DRL Dr Reddy's Laboratories ) regarding Zevalin, a radioimmunotherapy agent used in the treatment of non-Hodgkin's lymphoma non-Hodg·kin's lymphoma n. Any of various malignant lymphomas characterized by the absence of Reed-Sternberg cells. Non-Hodgkin's lymphoma . Zevalin (ibritumomab tiuxetan), which was initially approved in the US in 2002, is currently available in 37 countries worldwide. Nippon Schering has applied a new drug application for Zevalin with the Ministry of Health, Labor and Welfare, as of June 23, and aims to obtain approval at the earliest date possible. Upon receiving approval, the two companies will jointly promote and sell Zevalin in Japan. In particular, DRL will handle orders and distribution. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion